Following successful preclinical and phase 1 data [4, 9], the SOLAR-1 phase III randomized trial evaluated the efficacy of alpelisib plus fulvestrant in 572 patients with HR+/HER2− advanced BC who had received prior endocrine therapy [10]. Here, HR is linked to breast cancer.